Orca Bio has disclosed $250 million in funding, flooding its balance sheet with cash to buoy preparations for the ...

Nona Biosciences ("Nona"), a global biotechnology company advancing biologics discovery through innovative technology ...

Cell and gene therapies use the body's building blocks - cells and genetic material - to boost the immune system or correct ...

Glioblastoma remains one of the most challenging solid tumors to treat due to its highly immunosuppressive tumor microenvironment.

CK0804, a regulatory T cell therapy, received FDA orphan drug designation for myelofibrosis, supporting rare disease treatment development. Clinical study results showed significant reductions in ...

In an effort to extend financing support for patients seeking CAR-T cell therapy, Immuneel Therapeutics has partnered with healthcare crowdfunding platform Impact Guru, and healthcare-focussed lending ...

A new study maps the immune cell landscape of bone marrow in patients with multiple myeloma, a rare cancer that develops in ...

Orca Bio announces $250M in aggregate financing to support launch readiness leading up to the Orca-T® PDUFA date of April 6, 2026.

Researchers have developed a new class of antibodies that amplify the immune system’s ability to fight cancer. By clustering ...

H 2026 Catalyst Stack Anticipated to Validate Scalable, Off-the-Shelf CAR T in Oncology and Autoimmune Disease Interim ...

FREDERICK, Md., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, ...

MIAMI, FL / / January 9, 2026 / PromiCell, Inc. (the "Company"), a clinical-stage cellular immunotherapy company uniquely positioned to advance potentially curative cell therapies for cancer patients ...